#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis

A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.
Source: Venous Insufficiency 23. 4. 2020

News Dynamics of Allergy Development in Children

The prevalence of allergic diseases in children in developed countries has been steadily increasing in recent decades. Slovak authors attempted to describe the dynamics of the development of allergic symptoms in a prospective cohort of children who developed atopic dermatitis, rhinoconjunctivitis, wheezing, urticaria, or food allergy within the first 5 years of life.
Source: Allergic Reactions 1. 10. 2020

News Treatment of Comorbidities of Atopic Dermatitis in One Go and Where to Refer Candidates for Biologic Therapy

Patients suffering from atopic dermatitis (AD) along with allergic comorbidities typically require a fairly complex pharmacotherapy to manage their difficulties. However, their everyday lives can be significantly simplified with biological therapy.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 19. 10. 2020

News Post-COVID-19 Patient Care from the Perspective of Experts Across Fields

For many patients with COVID-19, overcoming the acute phase is crucial, but we now know that the disease may not end there. Some patients even manage the acute stage with very mild symptoms, and significant difficulties arise later in the form of 'post-COVID syndrome.' This issue was discussed in detail at a January webinar by leading experts from various fields.
Source: Cough Therapy 19. 3. 2021

News Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study

Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC) or to assess treatment response, liquid biopsy is essential for monitoring, as its results can affect the selection of targeted therapy. American authors present the case of a patient with advanced NSCLC initially treated with alectinib due to positive ALK gene rearrangement, whose therapy was switched to sotorasib after disease progression and the finding of the KRAS oncogene G12C mutation in a liquid biopsy.
Source: Lung Cancer 19. 6. 2023

News Risk Factors for Renal Cancer Formation After Kidney Transplantation

German authors in the below-cited work identified modifiable risk factors associated with the development of renal cell carcinoma (RCC) de novo in patients after kidney transplantation.
Source: Kidney Carcinoma 5. 11. 2021

News Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study

Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and possibly chronic inflammation. The study presented below is the first to compare the profile of inflammatory cytokines and eye irritation in patients using topical antiglaucoma drugs with and without preservatives.
Source: Treatment of Glaucoma 18. 2. 2021

News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.
Source: Heart Failure 3. 11. 2022

News How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?

Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolemia or mixed dyslipidemia, was registered in the European Union at the end of 2020. Internists and cardiologists can now share their first experiences with this therapy in real practice. Case reports from the Czech Republic have also been published in specialized literature.
Source: Chronic Heart Failure and Lipidology 12. 12. 2022

News Pharmacokinetic Comparison of Two EHL Products in Hemophilia A

According to a Canadian study published last year, certain pharmacokinetic differences were observed between two extended half-life factors.
Source: Hemophilia 8. 2. 2022

News Monitoring of Joint Health is an Important Part of Hemophilia Care

Joint health has become a key aspect of the quality of life for people with hemophilia. The possibilities of monitoring early joint damage in hemophiliacs were evaluated in a recently published British study.
Source: Hemophilia 18. 8. 2021

News Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?

Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by pegylation, which results in an approximately 1.5× prolonged biological half-life compared to standard half-life FVIII. Previous studies have already confirmed the favorable profile of this drug in prophylaxis for patients with hemophilia A. Recently published results of a prospective multicenter continuation study in children and adult patients under 75 years old with severe hemophilia A (baseline FVIII level < 1%) were based on an observation period averaging 2.2 years.
Source: Hemophilia 2. 11. 2020

News Safety and Tolerability of Bilastine in the Treatment of Chronic Urticaria in Children

Chronic urticaria is less common in pediatric patients compared to the acute form, but it always requires therapy due to bothersome chronic symptoms that reduce quality of life and disrupt daily activities of affected children. According to recent guidelines, the first-line treatment is non-sedating second-generation antihistamines, among which bilastine is included.
Source: Allergic Reactions 17. 8. 2020

News Efficacy of L. reuteri DSM 17938 in Treating Acute Gastroenteritis in Children

Diarrheal diseases are among the most common causes of death worldwide in children under 5 years of age. Effective and timely treatment is crucial in the case of acute gastroenteritis (AGE), which is why probiotics are attracting significant attention in the context of AGE therapy. A meta-analysis published last year in the journal Nutrients focused on the efficacy of Lactobacillus reuteri DSM 17938 in treating AGE in children from 3 months to 5 years old.
Source: GI, colic and microbiome 15. 7. 2020

News Biological treatment of psoriatic arthritis in the 1st line – results of the SPIRIT-H2H study after 1 year of follow-up

The SPIRIT-H2H study compared the efficacy of ixekizumab and adalimumab, either as monotherapy or with concomitant methotrexate (MTX), in patients with psoriatic arthritis (PsA) who had not been previously treated with biologics. The results of the recent work presented below after one year of follow-up suggest that the efficacy of ixekizumab remains the same regardless of the use of MTX, while the efficacy of adalimumab increases in combination with MTX.
Source: Biological Treatment 3. 5. 2021

News Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?

Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women. However, women in the USA who are indicated for this treatment have historically taken it less frequently and in lower doses than men. The current status and possible causes were investigated by the study presented below.
Source: Cardiovascular Risks 31. 1. 2020

News Collagen Turnover as a Biomarker of Hemophilia Treatment Efficacy

Over the past decades, hemophilia treatment has made significant progress—from factor therapy to prophylactic regimens and non-factor products, and even to gene therapy. Its development has greatly improved the quality of life for hemophiliacs and reduced the incidence of bleeding episodes. However, they cannot be completely eliminated, which is why further options for monitoring bleeding and joint status are still being explored. In addition to classical methods, biomarkers are attracting attention, but their practical use is still the subject of studies. A recently published work by a team of European and American experts, who assessed collagen turnover as a biomarker of treatment efficacy with rurioctocog alfa pegol, came with interesting results.
Source: Hemophilia 10. 6. 2024

News Issues of Adherence to Thromboprophylaxis with Enoxaparin in Patients with Sickle Cell Disease

Thromboembolic disease is one of the common complications in patients with sickle cell disease (SCD). However, a recently published study shows that patient adherence to prescribed thromboprophylaxis is not very high.
Source: Thromboprophylaxis 3. 1. 2024

News What Did 3 Years of Data from the Czech National COPD Database Reveal?

In December of last year, the Czech multicenter research database on COPD was completed. This was an extensive 5-year project in which researchers included 784 patients with significant chronic obstructive pulmonary disease (FEV1 ≤ 60%) from 14 centers. This represents approximately 1% of the total number of patients with this diagnosis in the Czech Republic, making the study sample fairly representative for obtaining data on treatment in Czech real practice. Three-year data are currently available. What have they shown so far? This was summarized during this year's Hradec Pulmonology Days by Dr. Jaromír Zatloukal, Ph.D., from the Clinic of Pulmonary Diseases and TB at the Faculty of Medicine, Palacký University and University Hospital Olomouc.
Source: Cough Therapy 24. 5. 2022

News New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations

Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i, gliflozins) and glucagon-like peptide 1 receptor agonists (GLP-1RA) have led to efforts to create new recommendations for their use in patients with type 2 diabetes mellitus (T2DM) for primary and secondary CV disease prevention. A recent review by American experts succinctly summarizes what current guidelines from American and European professional societies say on this subject.
Source: Diabetes 20. 12. 2021

News Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study

Several studies and meta-analyses in the past have pointed to a possible positive effect of low-molecular-weight heparins (LMWH) in the treatment of cancer. The RASTEN study therefore focused on the potential effect of enoxaparin in patients with small-cell lung cancer (SCLC).
Source: Thromboprophylaxis 18. 2. 2020

News The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel

Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA) indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. The efficacy of lurasidone has been confirmed by a number of clinical studies, compared to placebo and using active control with known antipsychotics (e.g., olanzapine or quetiapine). The aim of the recently published study was to define current possibilities of using lurasidone in the treatment of schizophrenia and to identify patient groups that would benefit the most from this therapy.
Source: Modern Treatment of Schizophrenia 24. 8. 2021

News Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study

Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor who achieved complete histological remission following denosumab treatment.
Source: Prevention of Bone Events 9. 4. 2022

News Overall Survival in Patients with Metastatic CRC During 1st-Line Anti-EGFR Treatment Depending on the Presence or Absence of Hypomagnesemia

Hypomagnesemia is one of the side effects of monoclonal antibody therapy against the epidermal growth factor receptor (EGFR). The study presented below examined overall survival in patients with metastatic primarily unresectable colorectal cancer (CRC) treated with anti-EGFR therapy depending on the presence or absence of hypomagnesemia.
Source: Colorectal Cancer 3. 10. 2022

News N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up

An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
Source: Hemophilia with Movement 4. 10. 2023

1 10 11 12 13 14 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#